Aptamer Group plc (AIM: APTA) announced on Wednesday that Twist Bioscience Corporation has launched its TrueAmp Library Preparation Kit incorporating Aptamer's proprietary Optimer binders to enable room-temperature stability within the workflow.

TrueAmp Library Preparation Kit is designed to enhance next-generation sequencing library amplification, combining Aptamer's Optimer binders with Twist Bioscience's in-house developed enzymes, including a proprietary ligase and a newly developed high-fidelity polymerase. Specialised polymerase is engineered to maximise genomic coverage in hard-to-sequence regions while maintaining high accuracy during DNA replication.

TrueAmp Library Preparation Kit delivers high yields from low-input or degraded samples, reducing amplification-induced errors and improving usable data output. The product has been validated with Twist HT-UDI adapter system, enabling up to 3,072 unique indexes, and with Twist UMI adapters to support accurate strand identification and multiplexing.

Development follows the non-exclusive licence granted by Aptamer in December 2025 for use of its Optimer inhibitor with a proprietary high-fidelity polymerase. The collaboration combines Twist Bioscience's synthetic biology capabilities with Aptamer's synthetic binder platform to target growth opportunities in the expanding next-generation sequencing market.

Headquartered in York, UK, Aptamer develops synthetic Optimer binders as alternatives to antibodies for applications in therapeutics, diagnostics and research. The company operates a fee-for-service model serving leading pharmaceutical and life sciences groups, while building a portfolio of partnered assets to generate future licensing and royalty revenues.